Golden Helix Receives NIH-SBIR Grant
By Bio-IT World Staff
March 26, 2019 | Golden Helix announced the receipt a NIH SBIR Grant 2R44GM128485-02 entitled “Automated and Guided Workflows for Clinical Testing Using NGS Assays.”
This is the second grant Golden Helix has received in the last nine months, totaling over $3.3 million in funding since the start of 2018.
“With the help of this grant, we will take the automation of the clinical interpretation of NGS data to the next level, focusing on germline diseases and cancer diagnostics,” Andreas Scherer, President, and CEO of Golden Helix, said in an official statement. “We are eternally grateful for the NIH’s incredible support we have received over the last couple of years.”
In September 2018, Golden Helix received a NIH Phase 2 SBIR Grant: “Integrating CNV analysis into a NextGen sequencing clinical analytics platform.” Scherer spoke with Bio-IT World shortly after about the trajectory of the company moving forward.
“Deep integration into clinical workflows has to occur,” Scherer said. “However, we don’t want to stop there. We are aiming to further improve our detection capabilities. There is still, from a technology perspective, more possible. We have now the ability to take that calculated risk and explore that further.”
The first results of the work based on this latest grant will be presented at AMP Global 2019, in Hong Kong this May.